Approved formulations exist
Semaglutide
GLP-1
A GLP-1 receptor agonist used in approved prescription medications for diabetes and/or weight management, depending on formulation and brand.
Next-Generation Weight Management · Austin
Retatrutide in Austin: What to Know About the Triple Agonist
Retatrutide has become one of the most talked-about medications in weight-management research. Unlike semaglutide or tirzepatide, retatrutide acts on three hormone-receptor pathways—GIP, GLP-1 and glucagon.
Here's what the research actually shows, how it differs from today's established options, and what Austin patients should understand before making decisions based on online hype.
One molecule · three pathways
Triplereceptor agonist
GIP
GLP-1
Glucagon
Educational overview · Retatrutide remains investigational as of September 19, 2026.
Quick answer
What Is Retatrutide?
Retatrutide is an investigational once-weekly medication being developed by Eli Lilly. It activates three hormone receptors involved in appetite, metabolism and blood-sugar regulation: GIP, GLP-1 and glucagon. Because it targets three receptor pathways, it is often described as a “triple agonist.”
As of September 19, 2026, retatrutide remains investigational and has not completed the regulatory approval process. Lilly has announced plans to submit it to the FDA in the first quarter of 2027; regulatory review will determine what happens next.
Search term, clarified
Is Retatrutide a “GLP-3”?
No. “GLP-3” is an informal internet nickname, not a scientific drug classification.
People searching for GLP-3 weight loss or retatrutide GLP-3 are usually referring to its three-target mechanism: GIP, GLP-1 and glucagon. The more accurate term is triple agonist.
- GIP
- Glucose-dependent insulinotropic polypeptide
- GLP-1
- Glucagon-like peptide-1
- Glucagon
- A separate metabolic hormone pathway
Mechanism comparison
Retatrutide vs. Tirzepatide vs. Semaglutide
Approved formulations exist
Tirzepatide
GIP + GLP-1
A dual-receptor agonist used in approved prescription medications.
Investigational
Retatrutide
GIP + GLP-1 + glucagon
A triple agonist currently being evaluated in late-stage clinical trials.
There has not been a direct clinical trial proving that retatrutide is universally “better” than semaglutide or tirzepatide for every patient.
Separate studies involve different populations, designs, doses and treatment durations.
The third pathway
What Makes Retatrutide Different?
Semaglutide acts primarily through GLP-1. Tirzepatide adds GIP. Retatrutide adds a third pathway: the glucagon receptor.
Researchers are studying the combined effect. It would be inaccurate to reduce the mechanism to “glucagon burns fat” or to promise a specific metabolic response.
01
Appetite
How hunger and food intake may change
02
Satiety
How fullness signals may be influenced
03
Energy balance
How intake and expenditure interact
04
Glucose metabolism
How the body regulates blood sugar
05
Weight reduction
How these combined pathways may affect body weight
Phase 3 evidence
What Have Retatrutide Clinical Trials Shown So Far?
Lilly has reported positive Phase 3 topline findings from its TRIUMPH program. The figures below are company-reported study averages—not guaranteed individual outcomes and not a substitute for completed regulatory review.
TRIUMPH-1
Phase 328.3%
about 70.3 lb
Adults with obesity or overweight plus at least one weight-related condition, without diabetes
12 mg group · average at 80 weeks
TRIUMPH-2
Phase 320.8%
up to about 49.6 lb
Adults with obesity or overweight and type 2 diabetes
12 mg group · average at 80 weeks
TRIUMPH-3
Phase 322.6%
up to about 55.8 lb
Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes
12 mg group · average at 80 weeks
TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 efficacy figures shown here are Lilly-reported Phase 3 topline results. They should not be described as full peer-reviewed publications unless and until detailed manuscripts complete peer review.
Read the evidence carefully
Don't Compare Weight-Loss Percentages Like a Scoreboard
Different medications are often studied in different populations, over different durations, at different starting weights and doses, and in people with different medical conditions.
A higher percentage in one trial does not automatically prove one medication is better for a particular individual.
Dual vs. triple agonist
Retatrutide vs. Tirzepatide: What's the Difference?
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity, making it a triple agonist.
Tirzepatide already has FDA-approved formulations; retatrutide remains investigational. Both have produced substantial average weight loss in clinical studies, but there are not enough direct comparative data to declare one universally superior.
Single vs. triple pathway
Retatrutide vs. Semaglutide
Semaglutide targets GLP-1 receptors, while retatrutide targets GIP, GLP-1 and glucagon receptors.
A broader receptor mechanism does not by itself establish what is appropriate for an individual. Medical history, goals, tolerability and the evidence for an approved treatment all matter.
Interest vs. evidence
Why Is Retatrutide Getting So Much Attention?
Interest and evidence are not the same thing.
Grace's goal is to help people distinguish published evidence, clinical-trial findings, online claims and individual medical decisions.
- 01A three-receptor mechanism
- 02Strong Lilly-reported Phase 3 topline findings
- 03Substantial social-media discussion
- 04Interest from people familiar with semaglutide and tirzepatide
- 05Research across multiple obesity-related conditions
Online products
What About Retatrutide Being Sold Online?
Products advertised online as “research peptides” or “retatrutide” are not the same thing as participation in Lilly's clinical development program. FDA states that retatrutide is not an approved drug and has specifically advised that it cannot be used in compounding under federal law.
Unapproved products do not undergo FDA review for safety, effectiveness and quality. This page does not provide acquisition, mixing, dosing or self-injection instructions.
Safety context
What Side Effects Have Been Reported in Retatrutide Studies?
Gastrointestinal effects have been among the commonly reported adverse events in incretin-based retatrutide trials. Reported symptoms have included:
Nausea
Diarrhea
Vomiting
Constipation
This is not a complete list. Study safety findings do not determine an individual's candidacy or risk. Treatment decisions belong in a discussion with an appropriate medical professional.
The larger conversation
Retatrutide Is One Part of a Much Bigger Weight-Loss Conversation
The most important question isn't simply, “What's the newest medication?”
It's what treatment strategy makes sense for your body—and what happens to your body composition while the weight comes off.
01Medical assessment
02Current prescription weight-management options
03InBody body-composition tracking
04Protein-forward nutrition guidance
05Hydration
06Lean-mass awareness
07Resistance exercise
08Follow-up
09Planning for facial and body changes during substantial weight loss
Beyond the scale
Weight Lost Doesn't Always Mean Fat Lost
Scale weight alone cannot tell you how much of a change came from fat mass, lean tissue or water. That's why Grace's broader weight-management philosophy includes body-composition monitoring rather than relying on scale weight alone.
The face during weight loss
What Happens to the Face During Major Weight Loss?
Significant weight reduction may make facial volume loss, skin laxity, jawline change and neck laxity more noticeable in some people. Those concerns are associated primarily with substantial weight loss rather than one medication or brand.
Start with education
Interested in Retatrutide? Start With the Right Questions.
Emerging research is not a candidate checklist. A useful conversation starts with evidence and your larger weight-management goals.
- 01How is retatrutide different from current options?
- 02What does the clinical evidence actually show?
- 03What weight-management treatments are available today?
- 04How should lean mass be monitored during substantial weight loss?
- 05What should I be doing with protein, nutrition and resistance exercise?
- 06What should I know about newer medications still in development?
Direct answers
Retatrutide Questions, Answered
Evidence & further reading
Regulatory status was checked against FDA materials. Development status and Phase 3 figures were checked against Lilly's official announcements. Published Phase 2 findings are separately identified as peer reviewed.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food & Drug Administration
- Bulk Drug Substances Used in CompoundingU.S. Food & Drug Administration
- TRIUMPH-1 Phase 3 Topline ResultsEli Lilly · company-reported topline findings
- TRIUMPH-2 and TRIUMPH-3 Phase 3 ResultsEli Lilly · July 2026 company-reported topline findings
- Triple-Hormone-Receptor Agonist Retatrutide for ObesityNew England Journal of Medicine · Phase 2, peer reviewed
- Retatrutide Phase 3 Trial RecordClinicalTrials.gov
Weight Management Is Moving Fast
Understand Your Options Before Chasing the Newest One
New weight-management treatments are developing quickly. Grace can help you understand how emerging therapies compare with today's options while keeping the focus on your individual goals, body composition and overall plan.
Visit
Northland Drive, Central Austin
Grace MedSpa and Body Solutions treats patients from one Austin location, convenient to Northwest Hills, Allandale, Rosedale and the Domain.
Hours
- Monday – Friday
- 9:00 AM – 5:00 PM
- Saturday – Sunday
- Closed